{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:35:03Z","timestamp":1780533303324,"version":"3.54.1"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Prostate cancer is one of the most prevalent cancers in men, leading to the second most common cause of death in men. Despite the availability of multiple treatments, the prevalence of prostate cancer remains high. Steroidal antagonists are associated with poor bioavailability and side effects, while non-steroidal antagonists show serious side effects, such as gynecomastia. Therefore, there is a need for a potential candidate for the treatment of prostate cancer with better bioavailability, good therapeutic effects, and minimal side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This current research work focused on identifying a novel non-steroidal androgen receptor antagonist through computational tools, such as docking and in silico ADMET analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Molecules were designed based on a literature survey, followed by molecular docking of all designed compounds and ADMET analysis of the hit compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A library of 600 non-steroidal derivatives (cis and trans) was designed, and molecular docking was performed in the active site of the androgen receptor (PDBID: 1Z95) using Auto- Dock Vina 1.5.6. Docking studies resulted in 15 potent hits, which were then subjected to ADME analysis using SwissADME. ADME analysis predicted three compounds (SK-79, SK-109, and SK-169) with the best ADME profile and better bioavailability. Toxicity studies using Protox-II were performed on the three best compounds (SK-79, SK-109, and SK-169), which predicted ideal toxicity for these lead compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This research work will provide ample opportunities to explore medicinal and computational research areas. It will facilitate the development of novel androgen receptor antagonists in future experimental studies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573409919666230626113346","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T05:17:35Z","timestamp":1687843055000},"page":"575-589","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Rationalized Approach to Design and Discover Novel Non-steroidal Derivatives through Computational Aid for the Treatment of Prostate Cancer"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-4693","authenticated-orcid":true,"given":"Shubham","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar- Delhi G.T. Road, Phagwara, Punjab, 144411, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Bioengineering &amp; Biosciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab, 144411, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar- Delhi G.T. Road, Phagwara, Punjab, 144411, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paranjeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"Rawla P.","year":"2019","unstructured":"Rawla P.; Epidemiology of prostate cancer. World J Oncol 2019,10(2),63-89","journal-title":"World J Oncol"},{"key":"ref=2","unstructured":"Available From: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (accessed 15 nov 2022)."},{"key":"ref=3","first-page":"1","author":"Hammerich K.H.","year":"2009","unstructured":"Hammerich K.H.; Ayala G.E.; Wheeler T.M.; Anatomy of the prostate gland and surgical pathology of prostate cancer 2009,1-10","journal-title":"Anatomy of the prostate gland and surgical pathology of prostate cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1272\/jnms.JNMS.2018_85-37","volume":"85","author":"Yasuoka S.","year":"2018","unstructured":"Yasuoka S.; Kimura G.; Toyama Y.; Moriya K.; Takahashi K.; Matsuoka R.; Shibayama K.; Obayashi K.; Inoue Y.; Shindo T.; Iigaya S.; Endo Y.; Akatsuka J.; Hayashi T.; Nakayama S.; Hamasaki T.; Inokuchi K.; Kondo Y.; A case of primary malignant lymphoma of the prostate gland presenting as right lower back pain and dysuria. J Nippon Med Sch 2018,85(4),236-240","journal-title":"J Nippon Med Sch"},{"key":"ref=5","first-page":"1269","volume":"59","author":"Keyes M.","year":"2013","unstructured":"Keyes M.; Crook J.; Morton G.; Vigneault E.; Usmani N.; Morris W.J.; Treatment options for localized prostate cancer. Can Fam Physician 2013,59(12),1269-1274","journal-title":"Can Fam Physician"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.disamonth.2014.02.003","volume":"60","author":"Saman D.M.","year":"2014","unstructured":"Saman D.M.; Lemieux A.M.; Nawal Lutfiyya M.; Lipsky M.S.; A review of the current epidemiology and treatment options for prostate cancer. Dis Mon 2014,60(4),150-154","journal-title":"Dis Mon"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.soncn.2011.07.002","volume":"1","author":"Dunn M.W.","year":"2011","unstructured":"Dunn M.W.; Kazer M.W.; Seminars in oncology nursing 2011,1(4),241-250","journal-title":"Seminars in oncology nursing"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1046\/j.1525-1497.2000.90842.x","volume":"15","author":"Holmboe E.S.","year":"2000","unstructured":"Holmboe E.S.; Concato J.; Treatment decisions for localized prostate cancer. J Gen Intern Med 2000,15(10),694-701","journal-title":"J Gen Intern Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00261959","volume":"16","author":"Okada K.","year":"1988","unstructured":"Okada K.; Oishi K.; Yoshida O.; Sudo K.; Kawase M.; Nakayama R.; Study of the effect of an anti-androgen (Oxendolone) on experimentally induced canine prostatic hyperplasia. Urol Res 1988,16(2),73-78","journal-title":"Urol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0094-0143(21)01398-7","volume":"18","author":"Goldenberg S.L.","year":"1991","unstructured":"Goldenberg S.L.; Bruchovsky N.; Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991,18(1),111-122","journal-title":"Urol Clin North Am"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41391-020-0220-8","volume":"23","author":"Beckmann K.","year":"2020","unstructured":"Beckmann K.; Garmo H.; Lindahl B.; Holmberg L.; Stattin P.; Adolfsson J.; Cruickshank J.K.; Van Hemelrijck M.; Spironolactone use is associated with lower prostate cancer risk: A population-wide case-control study. Prostate Cancer Prostatic Dis 2020,23(3),527-533","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","volume":"74","author":"Dhondt B.","year":"2019","unstructured":"Dhondt B.; Buelens S.; Van Besien J.; Beysens M.; De Bleser E.; Ost P.; Lumen N.; Abiraterone and spironolactone in prostate cancer: A combination to avoid. Acta Clin Belg 2019,74(6),439-444","journal-title":"Acta Clin Belg"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s11095-006-9024-3","volume":"23","author":"Gao W.","year":"2006","unstructured":"Gao W.; Kim J.; Dalton J.T.; Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006,23(8),1641-1658","journal-title":"Pharm Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","volume":"40","author":"Maurice-Dror C.","year":"2022","unstructured":"Maurice-Dror C.; Le Moigne R.; Vaishampayan U.; Montgomery R.B.; Gordon M.S.; Hong N.H.; DiMascio L.; Perabo F.; Chi K.N.; A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2022,40(2),322-329","journal-title":"Invest New Drugs"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003088-199834050-00005","volume":"34","author":"Mahler C.","year":"1998","unstructured":"Mahler C.; Verhelst J.; Denis L.; Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998,34(5),405-417","journal-title":"Clin Pharmacokinet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0968-0896(01)00421-7","volume":"10","author":"Ishioka T.","year":"2002","unstructured":"Ishioka T.; Kubo A.; Koiso Y.; Nagasawa K.; Itai A.; Hashimoto Y.; Novel non-steroidal\/non-anilide type androgen antagonists with an isoxazolone moiety. Bioorg Med Chem 2002,10(5),1555-1566","journal-title":"Bioorg Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2174\/1389557516666160118112448","volume":"16","author":"Kaur P.","year":"2016","unstructured":"Kaur P.; Khatik G.L.; Advancements in non-steroidal antiandrogens as potential therapeutic agents for the treatment of prostate cancer. Mini Rev Med Chem 2016,16(7),531-546","journal-title":"Mini Rev Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.phymed.2018.03.054","volume":"46","author":"Stanis\u0142awska I.J.","year":"2018","unstructured":"Stanis\u0142awska I.J.; Piwowarski J.P.; Granica S.; Kiss A.K.; The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide. Phytomedicine 2018,46,176-183","journal-title":"Phytomedicine"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/molecules26010056","volume":"26","author":"Kandil S.B.","year":"2020","unstructured":"Kandil S.B.; McGuigan C.; Westwell A.D.; Synthesis and biological evaluation of bicalutamide analogues for the potential treatment of prostate cancer. Molecules 2020,26(1),56","journal-title":"Molecules"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejmech.2019.01.054","volume":"167","author":"Kandil S.","year":"2019","unstructured":"Kandil S.; Lee K.Y.; Davies L.; Rizzo S.A.; Dart D.A.; Westwell A.D.; Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. Eur J Med Chem 2019,167,49-60","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jhet.3487","volume":"56","author":"Gomha S.M.","year":"2019","unstructured":"Gomha S.M.; Abdel-aziz H.M.; Badrey M.G.; Abdulla M.M.; efficient synthesis of some new 1, 3, 4\u2010thiadiazoles and 1, 2, 4\u2010triazoles linked to pyrazolylcoumarin ring system as potent 5\u03b1\u2010reductase inhibitors. J Heterocycl Chem 2019,56(4),1275-1282","journal-title":"J Heterocycl Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/j.bmcl.2016.04.058","volume":"26","author":"Mochona B.","year":"2016","unstructured":"Mochona B.; Qi X.; Euynni S.; Sikazwi D.; Mateeva N.; Soliman K.F.; Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett 2016,26(12),2847-2851","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.bmcl.2015.03.001","volume":"25","author":"Gamal El-Din M. M.","year":"2015","unstructured":"Gamal El-Din M. M.; El-Gamal M. I.; Abdel-Maksoud M. S.; Yoo K. H.; Oh C.-H.; Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives. Bioorg Med Chem Lett 2015,25(8),1692-1699","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.taap.2016.07.018","volume":"307","author":"Kharlyngdoh J.B.","year":"2016","unstructured":"Kharlyngdoh J.B.; Asnake S.; Pradhan A.; Olsson P.E.; TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol 2016,307,91-101","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1573409914666181019165821","volume":"16","author":"Kumar S.","year":"2020","unstructured":"Kumar S.; Khatik G.L.; Mittal A.; In silico molecular docking study to search new SGLT2 inhibitor based on dioxabicyclo [3.2. 1] octane scaffold. Curr Computeraided Drug Des 2020,16(2),145-154","journal-title":"Curr Computeraided Drug Des"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1039\/C5MB00499C","volume":"11","author":"Liu H.","year":"2015","unstructured":"Liu H.; An X.; Li S.; Wang Y.; Li J.; Liu H.; Interaction mechanism exploration of R-bicalutamide\/S-1 with WT\/W741L AR using molecular dynamics simulations. Mol Biosyst 2015,11(12),3347-3354","journal-title":"Mol Biosyst"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"13648","DOI":"10.1074\/jbc.M611711200","volume":"282","author":"Bohl C.E.","year":"2007","unstructured":"Bohl C.E.; Wu Z.; Miller D.D.; Bell C.E.; Dalton J.T.; Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007,282(18),13648-13655","journal-title":"J Biol Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.22159\/ajpcr.2018.v11s2.28512","volume":"11","author":"Dorice M.H.C.","year":"2018","unstructured":"Dorice M.H.C.; Khurana N.; Sharma N.; Khatik G.L.; Identification of possible molecular targets of potential anti-parkinson drugs by predicting their binding affinities using molecular docking. Asian J Pharm Clin Res 2018,11(14),28-32","journal-title":"Asian J Pharm Clin Res"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=30","year":"2014","unstructured":"Pharmacophore and ligand-based design with Biovia Discovery Studio. Dassault systemes Available from: https:\/\/www.3ds.com\/fileadmin\/PRODUCTS-SERVICES\/BIOVIA\/PDF\/Pharmacophore-Ligand-based-Design-with-BIOVIA-Discover y-Studio.pdf2014","journal-title":"Dassault systemes"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e1298","DOI":"10.1002\/wcms.1298","volume":"7","author":"Yuan S.","year":"2017","unstructured":"Yuan S.; Chan H.C.S.; Hu Z.; Using PYMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci 2017,7(2),e1298","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"ref=32","first-page":"135","volume":"14","author":"Jejurikar B.L.","year":"2021","unstructured":"Jejurikar B.L.; Rohane S.H.; Drug designing in discovery studio. Asian J Res Chem 2021,14(2),135-138","journal-title":"Asian J Res Chem"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.22270\/jddt.v9i2-s.2710","volume":"9","author":"Mishra S.","year":"2019","unstructured":"Mishra S.; Dahima R.; In vitro ADME studies of TUG-891, a GPR-120 inhibitor using SWISS ADME predictor. J Drug Deliv Ther 2019,9(2-s),366-369","journal-title":"J Drug Deliv Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017,7(1),42717","journal-title":"Sci Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"Banerjee P.","year":"2018","unstructured":"Banerjee P.; Eckert A.O.; Schrey A.K.; Preissner R.; ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018,46(W1),W257-W263","journal-title":"Nucleic Acids Res"},{"key":"ref=36a","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fchem.2018.00362","volume":"6","author":"Banerjee P.","year":"2018","unstructured":"Banerjee P.; Dehnbostel F.O.; Preissner R.; Prediction is a balancing act: Importance of sampling methods to balance sensitivity and specificity of predictive models based on imbalanced chemical data sets. Front Chem 2018,6,362","journal-title":"Front Chem"},{"key":"ref=36b","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"Pires D. E.","year":"2015","unstructured":"Pires D. E.; Blundell T. L.; Ascher D. B.; PKCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem 2015,58(9),4066-4072","journal-title":"J Med Chem"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666230626113346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218248\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666230626113346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T03:37:46Z","timestamp":1729654666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218248\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409919666230626113346","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}